Company Description
Enovis Corporation operates as a medical technology company focus on developing clinically differentiated solutions in the United States and internationally.
It operates through two segments: Prevention and Recovery, and Reconstructive segments. The company’s Prevention and Recovery segment offers orthopedic solutions and recovery sciences including rigid and soft orthopedic bracing, hot and cold therapy, bone growth stimulators, vascular therapy systems and compression garments, therapeutic shoes and inserts, electrical stimulators management, and physical therapy products which are used by orthopedic specialists, surgeons, primary care physicians, pain management specialists, physical therapists, podiatrists, chiropractors, athletic trainers, and other healthcare professionals.
Its Reconstructive segment operates surgical implant business, which includes a suite of reconstructive joint products for the hip, knee, shoulder, elbow, foot, ankle, and finger, as well as surgical productivity tools.
It also manufactures and distributes medical devices which are used for reconstructive surgery, rehabilitation, pain management, and physical therapy.
It distributes its products through independent distributors and directly under the ESAB and DJO brands.
The company was formerly known as Colfax Corporation. Enovis Corporation was founded in 1995 and is headquartered in Wilmington, Delaware.
| Country | United States |
| Founded | 1995 |
| IPO Date | May 8, 2008 |
| Industry | Medical Devices |
| Sector | Healthcare |
| Employees | 7,367 |
| CEO | Matthew Trerotola |
Contact Details
Address: 2711 Centerville Road, Suite 400 Wilmington, Delaware 19808 United States | |
| Phone | 302 252 9160 |
| Website | enovis.com |
Stock Details
| Ticker Symbol | ENOV |
| Exchange | NYSE |
| Stock Type | Common Stock |
| Fiscal Year | January - December |
| Reporting Currency | USD |
| CIK Code | 0001420800 |
| CUSIP Number | 194014502 |
| ISIN Number | US1940145022 |
| Employer ID | 54-1887631 |
| SIC Code | 3842 |
Key Executives
| Name | Position |
|---|---|
| Matthew L. Trerotola | Chief Executive Officer and Chairman |
| Phillip Benjamin Berry | Senior Vice President and Chief Financial Officer |
| Katie Sweet | Vice President of Corporate Communication |
| Tim Czartoski | President of U.S. Surgical and Global Product and Enabling Technologies |
| Davide Visentin | President of Enovis International Surgical |
| Terry D. Ross | Group President Prevention and Recovery |
| Brian P. Hanigan | Secretary |
| Louie Vogt | Group President of Reconstructive |
Latest SEC Filings
| Date | Type | Title |
|---|---|---|
| Apr 11, 2025 | DEFA14A | Additional definitive proxy soliciting materials and Rule 14(a)(12) material |
| Apr 11, 2025 | DEF 14A | Other definitive proxy statements |
| Apr 2, 2025 | 8-K | Current Report |
| Mar 14, 2025 | 8-K | Current Report |
| Feb 26, 2025 | 10-K | Annual Report |
| Feb 26, 2025 | 8-K | Current Report |
| Feb 26, 2025 | 8-K | Current Report |
| Feb 14, 2025 | SCHEDULE 13G | Filing |
| Feb 7, 2025 | SCHEDULE 13G/A | Filing |
| Feb 6, 2025 | SCHEDULE 13G | Filing |